BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 38284792)

  • 1. Swallowed topical corticosteroids for eosinophilic esophagitis: Utilization and real-world efficacy from the EoE CONNECT registry.
    Laserna-Mendieta EJ; Navarro P; Casabona-Francés S; Savarino EV; Amorena E; Pérez-Martínez I; Guagnozzi D; Blas-Jhon L; Betoré E; Guardiola-Arévalo A; Pellegatta G; Krarup AL; Perello A; Barrio J; Gutiérrez-Junquera C; Teruel Sánchez-Vegazo C; Fernández-Fernández S; Naves JE; Oliva S; Rodríguez-Oballe JA; Carrión S; Espina S; Llorente Barrio M; Masiques-Mas ML; Dainese R; Feo-Ortega S; Martín-Dominguez V; Fernández-Pacheco J; Pérez-Fernández MT; Ghisa M; Maniero D; Nantes-Castillejo Ó; Nicolay-Maneru J; Suárez A; Maray I; Llerena-Castro R; Ortega-Larrodé A; Alcedo J; Granja Navacerrada A; Racca F; Santander C; Arias Á; Lucendo AJ;
    United European Gastroenterol J; 2024 Jun; 12(5):585-595. PubMed ID: 38284792
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Swallowed Fluticasone Propionate Is an Effective Long-Term Maintenance Therapy for Children With Eosinophilic Esophagitis.
    Andreae DA; Hanna MG; Magid MS; Malerba S; Andreae MH; Bagiella E; Chehade M
    Am J Gastroenterol; 2016 Aug; 111(8):1187-97. PubMed ID: 27325220
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of Budesonide vs Fluticasone for Initial Treatment of Eosinophilic Esophagitis in a Randomized Controlled Trial.
    Dellon ES; Woosley JT; Arrington A; McGee SJ; Covington J; Moist SE; Gebhart JH; Tylicki AE; Shoyoye SO; Martin CF; Galanko JA; Baron JA; Shaheen NJ
    Gastroenterology; 2019 Jul; 157(1):65-73.e5. PubMed ID: 30872104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparisons of Fluticasone to Budesonide in the Treatment of Eosinophilic Esophagitis.
    Albert D; Heifert TA; Min SB; Maydonovitch CL; Baker TP; Chen YJ; Moawad FJ
    Dig Dis Sci; 2016 Jul; 61(7):1996-2001. PubMed ID: 27093866
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of eosinophlic esophagitis with swallowed topical corticosteroids.
    Nennstiel S; Schlag C
    World J Gastroenterol; 2020 Sep; 26(36):5395-5407. PubMed ID: 33024392
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Budesonide Orodispersible Tablets Maintain Remission in a Randomized, Placebo-Controlled Trial of Patients With Eosinophilic Esophagitis.
    Straumann A; Lucendo AJ; Miehlke S; Vieth M; Schlag C; Biedermann L; Vaquero CS; Ciriza de Los Rios C; Schmoecker C; Madisch A; Hruz P; Hayat J; von Arnim U; Bredenoord AJ; Schubert S; Mueller R; Greinwald R; Schoepfer A; Attwood S;
    Gastroenterology; 2020 Nov; 159(5):1672-1685.e5. PubMed ID: 32721437
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Topical steroids in eosinophilic esophagitis: Systematic review and meta-analysis of placebo-controlled randomized clinical trials.
    Murali AR; Gupta A; Attar BM; Ravi V; Koduru P
    J Gastroenterol Hepatol; 2016 Jun; 31(6):1111-9. PubMed ID: 26699695
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined and Alternating Topical Steroids and Food Elimination Diet for the Treatment of Eosinophilic Esophagitis.
    Reed CC; Safta AM; Qasem S; Angie Almond M; Dellon ES; Jensen ET
    Dig Dis Sci; 2018 Sep; 63(9):2381-2388. PubMed ID: 29380175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent insights on the use of topical steroids in eosinophilic esophagitis.
    Reddy A; Ashat D; Murali AR
    Expert Rev Gastroenterol Hepatol; 2020 Oct; 14(10):953-963. PubMed ID: 32567417
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel corticosteroid formulations in the treatment of eosinophilic esophagitis: what is the evidence?
    Walgraeve S; Vanuytsel T
    Acta Gastroenterol Belg; 2023; 86(3):437-448. PubMed ID: 37814560
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Eosinophilic esophagitis--treatment of eosinophilic esophagitis with drugs: corticosteroids.
    von Arnim U; Malfertheiner P
    Dig Dis; 2014; 32(1-2):126-9. PubMed ID: 24603395
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of Budesonide Orodispersible Tablets as Induction Therapy for Eosinophilic Esophagitis in a Randomized Placebo-Controlled Trial.
    Lucendo AJ; Miehlke S; Schlag C; Vieth M; von Arnim U; Molina-Infante J; Hartmann D; Bredenoord AJ; Ciriza de Los Rios C; Schubert S; Brückner S; Madisch A; Hayat J; Tack J; Attwood S; Mueller R; Greinwald R; Schoepfer A; Straumann A;
    Gastroenterology; 2019 Jul; 157(1):74-86.e15. PubMed ID: 30922997
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retrospective Comparison of Fluticasone Propionate and Oral Viscous Budesonide in Children With Eosinophilic Esophagitis.
    Fable JM; Fernandez M; Goodine S; Lerer T; Sayej WN
    J Pediatr Gastroenterol Nutr; 2018 Jan; 66(1):26-32. PubMed ID: 28489670
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of proton pump inhibitor therapy for eosinophilic oesophagitis in 630 patients: results from the EoE connect registry.
    Laserna-Mendieta EJ; Casabona S; Guagnozzi D; Savarino E; Perelló A; Guardiola-Arévalo A; Barrio J; Pérez-Martínez I; Lund Krarup A; Alcedo J; de la Riva S; Rey-Iborra E; Santander C; Arias Á; Lucendo AJ;
    Aliment Pharmacol Ther; 2020 Sep; 52(5):798-807. PubMed ID: 32677040
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic and Therapeutic Long-term Management of Eosinophilic Esophagitis- Current Concepts and Perspectives for Steroid Use.
    Greuter T; Alexander JA; Straumann A; Katzka DA
    Clin Transl Gastroenterol; 2018 Dec; 9(12):e212. PubMed ID: 30802222
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Swallowed topical corticosteroids reduce the risk for long-lasting bolus impactions in eosinophilic esophagitis.
    Kuchen T; Straumann A; Safroneeva E; Romero Y; Bussmann C; Vavricka S; Netzer P; Reinhard A; Portmann S; Schoepfer AM
    Allergy; 2014 Sep; 69(9):1248-54. PubMed ID: 24894658
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histologic and Clinical Effects of Different Topical Corticosteroids for Eosinophilic Esophagitis: Lessons from an Updated Meta-Analysis of Placebo-Controlled Randomized Trials.
    de Heer J; Miehlke S; Rösch T; Morgner A; Werner Y; Ehlken H; Becher H; Aigner A
    Digestion; 2021; 102(3):377-385. PubMed ID: 32610332
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Budesonide orodispersible tablets for induction of remission in patients with active eosinophilic oesophagitis: A 6-week open-label trial of the EOS-2 Programme.
    Miehlke S; Schlag C; Lucendo AJ; Biedermann L; Vaquero CS; Schmoecker C; Hayat J; Hruz P; Ciriza de Los Rios C; Bredenoord AJ; Vieth M; Schoepfer A; Attwood S; Mueller R; Burrack S; Greinwald R; Straumann A;
    United European Gastroenterol J; 2022 Apr; 10(3):330-343. PubMed ID: 35412032
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment outcomes for eosinophilic esophagitis in children with esophageal atresia.
    Chan LJ; Tan L; Dhaliwal J; Briglia F; Clarkson C; Krishnan U
    Dis Esophagus; 2016 Aug; 29(6):563-71. PubMed ID: 25872589
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomised, double-blind trial comparing budesonide formulations and dosages for short-term treatment of eosinophilic oesophagitis.
    Miehlke S; Hruz P; Vieth M; Bussmann C; von Arnim U; Bajbouj M; Schlag C; Madisch A; Fibbe C; Wittenburg H; Allescher HD; Reinshagen M; Schubert S; Tack J; Müller M; Krummenerl P; Arts J; Mueller R; Dilger K; Greinwald R; Straumann A
    Gut; 2016 Mar; 65(3):390-9. PubMed ID: 25792708
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.